deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT01872988

Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma

Sponsor: Gilead Sciences

Conditions Chronic Hepatitis B Hepatocellular Carcinoma
Interventions Placebo Tenofovir
Updated 6 times since 2017 Last updated: Sep 3, 2014 Started: Sep 30, 2012 Primary completion: Feb 28, 2018 Completion: Feb 28, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficult in patient enrollment

Other terminated trials from Gilead Sciences

See all terminations from Gilead Sciences

Other Chronic Hepatitis B trials with similar outcome

Browse all Chronic Hepatitis B trials

A PHASE3 clinical study on Chronic Hepatitis B and Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Gilead Sciences and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 9 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
  • Taichung Veterans General Hospital
  • Taipei Institute of Pathology
Data source: Taichung Veterans General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations